首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1037篇
  免费   72篇
  国内免费   3篇
财政金融   239篇
工业经济   56篇
计划管理   163篇
经济学   262篇
综合类   22篇
运输经济   18篇
旅游经济   17篇
贸易经济   218篇
农业经济   25篇
经济概况   92篇
  2023年   21篇
  2022年   5篇
  2021年   25篇
  2020年   31篇
  2019年   37篇
  2018年   62篇
  2017年   48篇
  2016年   64篇
  2015年   37篇
  2014年   41篇
  2013年   156篇
  2012年   47篇
  2011年   87篇
  2010年   87篇
  2009年   42篇
  2008年   53篇
  2007年   31篇
  2006年   34篇
  2005年   31篇
  2004年   19篇
  2003年   17篇
  2002年   13篇
  2001年   13篇
  2000年   11篇
  1999年   9篇
  1998年   11篇
  1997年   9篇
  1996年   7篇
  1995年   7篇
  1994年   5篇
  1992年   3篇
  1991年   4篇
  1990年   2篇
  1988年   2篇
  1987年   1篇
  1986年   1篇
  1985年   2篇
  1984年   1篇
  1983年   2篇
  1982年   3篇
  1981年   3篇
  1980年   2篇
  1979年   2篇
  1978年   5篇
  1976年   2篇
  1975年   7篇
  1974年   5篇
  1969年   1篇
  1968年   1篇
  1958年   1篇
排序方式: 共有1112条查询结果,搜索用时 31 毫秒
1.
Aims: The EINSTEIN-Extension trial (EINSTEIN-EXT) found that continued treatment with rivaroxaban for an additional 6 or 12 months (vs placebo) after 6–12 months of initial anticoagulation significantly reduced the risk of recurrent venous thromboembolism (VTE) with a small non-significant increased risk of major bleeding (none fatal or in critical site). This study aimed to compare total healthcare cost between rivaroxaban and placebo, based on the EINSTEIN-EXT event rates.

Methods: Total healthcare cost was calculated as the sum of treatment and clinical event costs from a US managed care perspective. Treatment duration and event rates were obtained from the EINSTEIN-EXT study. Adjustment on treatment duration was made by assuming a 10% non-adherence rate. Drug costs were based on wholesale acquisition costs. Cost estimates for clinical events (i.e. recurrent deep vein thrombosis [DVT], recurrent pulmonary embolism, major bleeding, clinically relevant non-major bleeding) were determined from the literature. Results were examined over a ±20% range of each cost component and over 95% confidence intervals (CIs) of event rate differences in deterministic (one-way) and probabilistic sensitivity analyses (PSA).

Results: Total healthcare cost was $1,454 lower for rivaroxaban-treated (vs placebo-treated) patients in the base-case, with a lower clinical event cost fully offsetting drug cost. The cost savings of recurrent DVT alone (–$3,102) was greater than drug cost ($2,723). Total healthcare cost remained lower for rivaroxaban in the majority (73%) of PSA (cost difference [95% CI]?=?–$1,454 [–$2,396, $1,231]).

Limitations: This study was conducted over the 1-year observation period of the EINSTEIN-EXT trial, which limited “real-world” applicability and examination of long-term economic impact. Assumptions on drug and clinical event costs were US-based and, thus, not applicable to other healthcare systems.

Conclusions: Total healthcare costs were estimated to be lower for patients continuing rivaroxaban therapy compared to those receiving placebo in VTE patients who had completed 6–12 months of VTE treatment.  相似文献   
2.
中国现阶段的工业品市场营销模式初探   总被引:1,自引:0,他引:1  
随着中国市场经济的快速发展、科技水平的提高以及中国加入WTO,工业品的市场竞争将更加激烈。对于中国现阶段的工业品来讲,由于行业、企业、产品特点及销售对象不同,各公司的营销策略各有不同,尤其对市场营销模式需要进一步探索。  相似文献   
3.
The deregulation of foreign banks in Japan, although corresponding in broad outline to world-wide trends, has diverged substantially in many particulars from patterns seen elsewhere. It has tended to be excruciatingly slow and piecemeal and to have been of minimal benefit to foreign banks. A review of this process leads to the conclusion that these characteristics result from organisational and political-bureaucratic factors inherent to the Japanese style of government which is, in turn, partially a reflection of Japanese culture. Although these non-economic factors have influenced the specific pattern of change, its overall direction appears to have been consistent with the broader national interest.The authors wish to acknowledge financial support from the Social Science and Humanities Research Council of Canada, the Florsheimer Center for Policy Studies, and the Krueger Center for Financial Research.  相似文献   
4.
The role of tourism is of vital economic importance, particularly for small countries with a privileged geographical location and favourable weather conditions. This paper examines the importance of tourism as a conditioning factor for higher regional growth in Portugal by employing the conditional convergence hypothesis of Barro and Sala-i-Martin, associated with the endogenous growth theory. The panel data estimation approach provides evidence of the positive impact of tourism (through the accommodation capacity) on the growth in per-capita income among the Portuguese regions, increasing the rate of convergence. Therefore, tourism can be considered as an alternative source for stimulating higher regional growth in Portugal, if the supply characteristics of this sector are improved.  相似文献   
5.
6.
7.
8.
陕西民间资金流失问题研究   总被引:1,自引:0,他引:1  
摘要:游离于国家计划之外的民间资金由于不受国家监管,流动的隐蔽性极强。在趋利动机的支配下,必然出现资金流向高利润率地区,从而出现经济不发达地区民间资金的大量流出。虽然西部大开发战略已实施四年有余,陕西民间资金却出现了向外流失的现象,找出其流出的渠道和原因,引导民间资金回流、支持陕西经济发展是目前急需解决的问题。  相似文献   
9.
Free Entry under Uncertainty   总被引:1,自引:0,他引:1  
When focusing on firm’s risk-aversion in industry equilibrium, the number of firms may be either larger or smaller when comparing market equilibrium with and without price uncertainty. In this paper, we introduce risk-averse firms under cost uncertainty in a model of spatial differentiation and show that the impact of uncertainty will increase the number of firms in an industry. With increased uncertainty, the risk premium of the marginal buyer increases by more than the risk premium of the average buyer, so that the price increases by more than the risk premium. When turning to the free entry game, we find that the market generates too many firms.  相似文献   
10.
我国建筑业全生命周期价值链的应用研究   总被引:4,自引:0,他引:4  
左进  韩洪云 《价值工程》2004,23(6):43-46
长期以来,我国建筑业缺乏对全生命周期价值链管理的整体关注,价值链中各个环节相互脱节,没有共同的价值目标,导致了成本较高的现状。本文旨在通过对建筑业全生命周期价值链的分析,拓展我国建筑业成本管理的关注面。并通过工程总承包模式对现有价值链进行优化,把勘察、设计、施工归集在同一个主体下管理,提高用户对建筑产品的满意度,降低产品成本。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号